StreetSmart Live! Presents Frank Holmes’ Virtual Junior Mining Expo on 11/12/2020. Learn More
RVV:TSX.V; RVVTF:OTCMKTS

Revive Therapeutics Ltd.

Revive is a life sciences company focused on the research and development of therapeutics for infectious diseases and rare disorders, and it is prioritizing drug development efforts to take advantage of several regulatory incentives awarded by the FDA such as Orphan Drug, Fast Track, Breakthrough Therapy and Rare Pediatric Disease designations. Currently, the company is exploring the use of Bucillamine for the potential treatment of infectious diseases, with an initial focus on severe influenza strains including COVID-19. With its recent acquisition of Psilocin Pharma Corp., Revive is advancing the development of Psilocybin-based therapeutics in various diseases and disorders. Revive's cannabinoid pharmaceutical portfolio focuses on rare inflammatory diseases and the company was granted FDA orphan drug status designation for the use of Cannabidiol (CBD) to treat autoimmune hepatitis (liver disease) and to treat ischemia and reperfusion injury from organ transplantation.
RVV:TSX.V RVVTF:OTCMKTS

Expert Comments:

Revive Therapeutics anticipates that more than 200 patients will complete its Phase 3 clinical trial of Bucillamine in patients with mild-moderate COVID-19 by the end of December 2020 and stated that those results will help identify the best dosage levels for the rest of the trial.
read more >
Revive Therapeutics will use these products in future studies and clinical trials.
read more >
Enrollment for the study evaluating Revive Therapeutics' Bucillamine can now begin.
read more >
Revive Therapeutics provides an update on its psychedelics therapeutics programs.
read more >
Through this program of Revive Therapeutics, qualifying patients will receive Bucillamine, and the biopharma will obtain safety and efficacy data.
read more >
Revive Therapeutics reported it has entered into clinical trial agreement with the University of Wisconsin-Madison to evaluate the use of psilocybin for the treatment of methamphetamine use disorder.
read more >
Revive Therapeutics reported that a renowned independent institutional review board has approved its proposed Phase 3 clinical trial protocol for Bucillamine in COVID-19.
read more >
Revive Therapeutics reported it signed a MOU with Attwill Medical Solutions Sterilflow to be a clinical packaging and distribution resource for its Phase 3 clinical trial of Bucillamine in COVID-19.
read more >
This development is a technical milestone for Revive Therapeutics and its drug delivery technology.
read more >
Revive Therapeutics is now "finalizing agreements and aligning resources to initiate the Phase 3 clinical trial in September."
read more >

Edward Vranic, Seeking Alpha

(8/5/20)
"Revive Therapeutics Ltd. received U.S. Food and Drug Administration signoff to start a Phase 3 trial on Bucillamine for mild to moderate cases of COVID-19. . .every COVID-19 speculative trader should consider adding the company to their watchlist. Due to the short length of the study period, it shouldn't be long after enrollment before investors start to see results."

Revive Therapeutics' trial will test Bucillamine in patients with mild to moderate COVID-19.
read more >
Revive Therapeutics met with Health Canada to discuss how best to proceed.
read more >
Revive Therapeutics is focused on infectious diseases as well as treatments using psilocybin-based formulations.
read more >

All Penny Stocks

(5/14/20)
Revive Therapeutics Ltd. is a life sciences company focused on the research and development of therapeutics for infectious diseases and rare disorders. The company is exploring the use of Bucillamine for the potential treatment of COVID-19. . .with its recent acquisition of Psilocin Pharma Corp., Revive is advancing the development of Psilocybin-based therapeutics in various diseases and disorders. . .the company's cannabinoid pharmaceutical portfolio focuses on rare inflammatory diseases, with the company being granted FDA orphan drug status designation for the use of Cannabidiol (CBD) to treat autoimmune hepatitis (liver disease) and. . .ischemia and reperfusion injury from organ transplantation.


The information provided above is from analysts, newsletters and other contributors. Please contact the company and visit its website before making an investment decision.See disclaimer for more details.

Investing Highlights
 
Strong IP in infectious diseases, psilocybin, and cannabis
 
Phase 2 for use of Bucillamine to treat gout and moving to Phase
 
Undervalued next to peers
catalyst Calendar
Q3
2020
Q3
2020
Partnership with University of Wisconsin in clinical studies with psillocybin
Revive Therapeutics Ltd. Content